New study tracks Polatuzumab's Real-World impact on blood cancer in 1,000 chinese patients
NCT ID NCT05954910
First seen Nov 18, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study follows about 1,000 Chinese adults with diffuse large B-cell lymphoma (a type of blood cancer) to see how well the drug polatuzumab works in everyday medical practice. Researchers will measure how long the cancer stays under control and track side effects. The study includes patients who are older or frail, those who are not, and those whose cancer has returned or not responded to prior treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Inner Mongolia Medical University
Hohhot, 010000, China
-
Beijing Hospital of Ministry of Health
Beijing, 100730, China
-
Beijing Tongren Hospital, Capital Medical University
Beijing, 100730, China
-
China Medical University (CMU) First Affiliated Hospital
Shenyang, 110001, China
-
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, 710061, China
-
Guizhou Cancer Hospital
Guiyang, 550004, China
-
Hainan Cancer Hospital
Haikou, China
-
Henan Cancer Hospital
Zhengzhou, China
-
Jiangsu Cancer Hospital
Nanjing, 211100, China
-
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)
Nanjing, 210029, China
-
Jiangxi Cancer Hospital
Nanchang, 330029, China
-
Peking Union Medical College Hospital
Beijing, 100032, China
-
Peking University Third Hospital
Beijing, 100191, China
-
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, 200025, China
-
Shanxi Province Cancer Hospital
Taiyuan, 030013, China
-
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
Chengdu, 610072, China
-
The Affiliated Hospital Of Qingdao University
Qingdao, DUMMY_VALUE, China
-
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
-
The First Bethune Hospital of Jilin University
Changchun, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
-
Third Xiangya Hospital of Central South University
Changsha, China
-
Tianjin Cancer Hospital
Tianjin, 300060, China
-
Tianjin Medical University General Hospital
Tianjin, 300052, China
-
Tongji Hospital of Tongji University
Shanghai, 200065, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430022, China
-
Wuxi People's Hospital
Wuxi, 214023, China
-
Xiangya Hospital of Centre-South University
Changsha, 410008, China
-
Xinjiang Medical University Cancer Hospital
Ürümqi, 830011, China
-
Zhujiang Hospital, Southern Medical University
Guangzhou, 510280, China
Conditions
Explore the condition pages connected to this study.